Lexaria Bioscience (LEXX) Revenue (2017 - 2026)
Lexaria Bioscience (LEXX) posted Revenue of $20000.0 for Q1 2026, down 88.51% sequentially from $174000.0 in Q3 2025, and down 88.51% YoY from $174000.0 in Q1 2025.
Lexaria Bioscience (LEXX) Revenue (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported Revenue for 10 years, with the latest figure at $20000.0 in Q1 2026.
- Quarterly Revenue fell 88.51% year-over-year to $20000.0 in Q1 2026, while the trailing twelve-month figure through May 2026 was $194000.0 (down 68.5% YoY) and the FY2025 annual result came in at $705923.0, up 52.05% from the prior year.
- Revenue declined to $20000.0 in Q1 2026 per LEXX's latest filing, from $174000.0 in the prior quarter.
- Over five years, Revenue peaked at $183923.0 in Q4 2024 and troughed at $20000.0 in Q1 2026.
- A 5-year average of $103620.4 and a median of $98726.0 in 2022 frame the typical range for Revenue.
- The sharpest annual moves came in 2024 and 2026: Revenue soared 624.09% in 2024, then plunged 88.51% in 2026.
- Over 5 years, Revenue stood at $97735.0 in 2022, then soared by 54.78% to $151278.0 in 2023, then grew by 21.58% to $183923.0 in 2024, then dropped by 5.4% to $174000.0 in 2025, then slumped by 88.51% to $20000.0 in 2026.
- According to Business Quant data, Revenue over the past three periods registered $20000.0, $174000.0, and $174000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Lexaria Bioscience | 10.63 Mn | 7.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 20,000.00 |
| Aug 31, 2025 | 174,000.00 |
| May 31, 2025 | 174,000.00 |
| Feb 28, 2025 | 174,000.00 |
| Nov 30, 2024 | 183,923.00 |
| Aug 31, 2024 | 84,000.00 |
| May 31, 2024 | 84,000.00 |
| Feb 29, 2024 | 145,000.00 |
| Nov 30, 2023 | 151,278.00 |
| Aug 31, 2023 | 30,741.00 |
| May 31, 2023 | 77,707.00 |
| Feb 28, 2023 | 20,025.00 |
| Nov 30, 2022 | 97,735.00 |
| Aug 31, 2022 | 111,150.00 |
| May 31, 2022 | 99,717.00 |
| Feb 28, 2022 | 30,650.00 |
| Nov 30, 2021 | 13,880.00 |
| Aug 31, 2021 | 31,021.00 |
| May 31, 2021 | 204,055.00 |
| Feb 28, 2021 | 192,006.00 |